Advertisement

Organisation › Details
Adrenomed AG
Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Adrecizumab (INN: enibarcimab) is a first-in-class non-blocking monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock. *
![]() |
Start | 2010-10-20 established |
![]() |
Industry | Adrecizumab |
Industry 2 | drug development | |
![]() |
Person | Jones, Richard (Adrenomed 202203– CEO before Fusion Antibodies formerly Novartis + GSK + Genzyme + Shire) |
Person 2 | Bergmann, Andreas (Sphingotec GmbH 201301 Managing Director) | |
![]() |
Region | Hennigsdorf |
Country | Germany | |
Street | 15a Neuendorfstr. | |
City | 16761 Hennigsdorf | |
Tel | +49-3302-207780 | |
Address record changed: 2022-09-17 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Adrenomed AG. (7/12/22). "Press Release: Adrenomed Appoints David Germonpré as Chief Financial Officer". Zurich. | ||
Record changed: 2024-12-29 |
Advertisement

More documents for Adrenomed AG
- [1] Adrenomed AG. (4/10/24). "Press Release: AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock". Hennigsdorf....
- [2] InfanDx AG. (9/1/22). "Press Release: InfanDx AG Appoints Nicole Witzmann as Chief Financial Officer". Cologne, Berlin & Boston, MA....
- [3] Adrenomed AG. (7/12/22). "Press Release: Adrenomed Appoints David Germonpré as Chief Financial Officer". Zurich....
- [4] Scienion GmbH. (6/1/22). "Press Release: Scienion Appoints Frauke Hein as CEO". Berlin....
- [5] Adrenomed AG. (3/15/22). "Press Release: Adrenomed Supervisory Board Appoints Dr. Richard Jones as CEO". Hennigsdorf....
- [6] Adrenomed AG. (1/4/21). "Press Release: Adrenomed Supervisory Board Appoints Dr. Wolfgang Baiker as CEO". Hennigsdorf....
- [7] Adrenomed AG. (11/30/20). "Press Release: Adrenomed Closes EUR 22 Million Equity Financing to Accelerate Development of Adrecizumab (HAM8101) and Provides Business Update". Hennigsdorf....
- [8] Adrenomed AG. (2/21/20). "Press Release: Adrenomed Announces Positive Top-Line AdrenOSS-2 Phase II Results with Adrecizumab in Septic Shock". Hennigsdorf....
- [9] Adrenomed AG. (9/26/19). "Press Release: Adrenomed Completes Full Enrollment with 300 Patients in AdrenOSS-2 Trial with Adrecizumab in Septic Shock". Hennigsdorf....
- [10] Adrenomed AG. (8/29/19). "Press Release: Adrenomed Supervisory Board Appoints Jens Schneider-Mergener as CEO and Jens Zimmermann, CMO, Joins the Executive Board". Hennigsdorf....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top